Official Website: Recursion Mission Page
source confidence: Medium status: Useful updated 2026-05-09
Summary
Recursion's mission page describes its AI drug-discovery approach, Recursion OS, multimodal biological and chemical data, pipeline focus, BioHive-2 supercomputer, and Salt Lake City headquarters.
Useful Claims
- Recursion says traditional drug discovery has high clinical failure rates, long timelines, and high cost.
- The page describes more than 50 petabytes of multimodal data across phenomics, transcriptomics, proteomics, ADME, and de-identified patient data.
- The page describes BioHive-2 as the most powerful supercomputer in pharma and notes a 2025 Top500 ranking.
- The page lists the Salt Lake City address.
Verbatim
"In traditional drug discovery, 90% of drugs fail in clinical trials, after more than a decade in development and ~$2 billion in costs." — Platform page, problem statement
">50 petabytes of high-quality, multimodal data" — Platform page, data scale
"Built in partnership with NVIDIA, BioHive-2 ranks as the 76th most powerful supercomputer by the Top500 list in 2025." — Platform page, BioHive-2
"With this system, we’re able to identify hit candidates in weeks, instead of years, and for thousands of dollars as opposed to millions." — Platform page, discovery process
Reliability Notes
This is an official company page, so it is reliable for how Recursion represents itself and useful for basic facts. It is not neutral evidence for clinical efficacy or platform superiority.